Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.64 |
| ▸ | CD4 | P01730 | 2/20 | 0.58 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9851544 | 0.90 | CYP2D6 (0.69) | CYP2D6USP2CD4SORT1TSHR | |
| SCHEMBL9851568 | 0.82 | PKM (0.63) | TSHRGAAMEN1KMT2ALMNA | |
| SCHEMBL3970094 | 0.82 | LMNA (0.73) | CD4SORT1TSHRGAALMNA | |
| SCHEMBL19991949 | 0.82 | LMNA (0.73) | CD4SORT1TSHRGAALMNA | |
| SCHEMBL3974277 | 0.82 | LMNA (0.73) | CD4SORT1TSHRGAALMNA | |
| SCHEMBL8036144 | 0.82 | LMNA (0.73) | CD4SORT1TSHRGAALMNA | |
| SCHEMBL13925192 | 0.80 | CD4 (0.81) | CD4SORT1TSHRGAALMNA | |
| SCHEMBL13925209 | 0.78 | CD4 (0.80) | CD4SORT1TSHRGAALMNA | |
| SCHEMBL14892935 | 0.78 | GAA (0.55) | CYP2D6USP2CD4SORT1TSHR | |
| SCHEMBL10914673 | 0.76 | TSHR (0.81) | CD4SORT1TSHRGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964949-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3932917-A2 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | The Global Alliance for TB Drug Development, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190023716-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-20180237449-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2018-06-28 | — | — | US | disclosed |
| EP-3334729-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND THEIR USE AS METAP2 INHIBITORS | Zafgen, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3307268-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | The Global Alliance for TB Drug Development Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9944613-B2 | Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944613-B2 | Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944613-B2 | Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2018-03-22 | — | — | US | disclosed |
| WO-2017027687-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND THEIR USE AS METAP2 INHIBITORS | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017015106-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141817-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964949-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THPO, TBCD, OXA1L | CYP2D6 1393/4885USP2 4770/4885CD4 143/4885 |
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | CYP2D6 1393/4885USP2 4770/4885CD4 143/4885 |
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | CYP2D6 1016/4885USP2 1260/4885CD4 4041/4885 |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | CYP2D6 1393/4885USP2 4770/4885CD4 143/4885 |
| US-20180237449-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | CYP2D6 1016/4885USP2 1260/4885CD4 4041/4885 |
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | CYP2D6 1016/4885USP2 1260/4885CD4 4041/4885 |
| US-20190023716-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | CYP2D6 1016/4885USP2 1260/4885CD4 4041/4885 |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THPO, TBCD, OXA1L | CYP2D6 1393/4885USP2 4770/4885CD4 143/4885 |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, DBH | CYP2D6 1098/4885USP2 75/4885CD4 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.